Wealth Enhancement Advisory Services LLC acquired a new stake in shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 10,000 shares of the company’s stock, valued at approximately $28,000.
Separately, Dauntless Investment Group LLC bought a new position in OKYO Pharma in the 1st quarter worth approximately $2,526,000. 2.97% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
OKYO has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of OKYO Pharma in a research note on Tuesday, September 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of OKYO Pharma in a report on Wednesday, October 8th. Zacks Research upgraded OKYO Pharma to a “hold” rating in a report on Tuesday, September 16th. Finally, Wall Street Zen upgraded OKYO Pharma to a “hold” rating in a report on Saturday, August 9th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $7.00.
OKYO Pharma Price Performance
OKYO stock opened at $2.00 on Tuesday. OKYO Pharma Limited Sponsored ADR has a twelve month low of $0.90 and a twelve month high of $3.35. The business’s 50-day simple moving average is $2.33 and its 200 day simple moving average is $2.10.
About OKYO Pharma
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.
Featured Stories
- Five stocks we like better than OKYO Pharma
- How to Buy Cheap Stocks Step by Step
- FICO’s Big Dip Could Be the Best Buying Chance of the Year
- 3 Defense Stocks Set to Benefit From Increased Military Spending
- D-Wave: Reevaluating the Short Seller’s Case After the Downgrade
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Datavault: A Speculative AI Play, But Beware of Volatility
Want to see what other hedge funds are holding OKYO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO – Free Report).
Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
